XML 43 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 16 - Share Based Compensation
12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
16.
S
HARE
BASED COMPENSATION
 
O
ur employees and non-employee directors participate in the Amended and Restated
2014
Equity Participation Plan of Civeo Corporation (the Civeo Plan). The Civeo Plan authorizes our Board of Directors and the Compensation Committee of our Board of Directors to approve grants of options, awards of restricted shares, performance awards and dividend equivalents, awards of deferred shares, and share payments to our employees and non-employee directors.
No
more than
14.0
million Civeo common shares
may
be awarded under the Civeo Plan.
 
S
hare-based compensation expense recognized in the years ended
December 
31,
2017,
2016
and
2015
totaled
$15.4
million,
$9.9
million and
$5.6
million, respectively. Share-based compensation expense is reflected in Selling, general and administrative (SG&A) expense in our consolidated statements of operations. The total income tax benefit recognized in the consolidated statements of operations for share based compensation arrangements was approximately zero, $
0.6
million and $
0.3
million for the years ended
December 31, 2017,
2016
and
2015,
respectively.
 
Options
to Purchase Common Shares
 
No
options were awarded in
2017,
2016
or
2015.
The following table presents the changes in stock options outstanding and related information for our employees during the years ended
December 31, 2017,
2016
and
2015:
 
   
 
 
 
 
Options
   
Weighted
Average
Exercise
Price Per
Share
   
 
Weighted
Average
Contractual
Life (Years)
   
 
 
Intrinsic
Value
(Thousands)
 
Outstanding Options at
December 31, 2014
   
532,926
    $
11.03
     
3.4
    $
66,130
 
Granted
   
--
     
--
     
 
     
 
 
Exercised
   
(137,771
)    
3.63
     
 
     
 
 
Forfeited / Expired
   
(4,821
)    
16.43
     
 
     
 
 
Outstanding Options at December 31, 201
5
   
390,334
    $
13.58
     
3.5
    $
--
 
Granted
   
--
     
--
     
 
     
 
 
Exercised
   
--
     
--
     
 
     
 
 
Forfeited / Expired
   
(224,448
)    
10.33
     
 
     
 
 
Outstanding Options at December 31, 201
6
   
165,886
    $
17.98
     
4.6
    $
--
 
Granted
   
--
     
--
     
 
     
 
 
Exercised
   
--
     
--
     
 
     
 
 
Forfeited / Expired
   
(20,085
)    
18.10
     
 
     
 
 
Outstanding Options at December 31, 201
7
   
145,801
    $
17.97
     
4.5
    $
--
 
                                 
Exercisable Options at December 31, 201
6
   
145,804
    $
17.67
     
4.4
    $
--
 
Exercisable Options at December 31, 201
7
   
139,491
    $
17.79
     
4.2
    $
--
 
                                 
 
The
total intrinsic value of options exercised by our employees during
2017,
2016
and
2015
was
zero
,
zero
and less than
$100,000,
respectively. The tax benefits realized for the tax deduction from options exercised during
2017,
2016
and
2015
totaled zero,
zero
and less than
$100,000,
respectively.
 
At
December 31,
201
7,
unrecognized compensation cost related to options was less than
$100,000,
which is expected to be recognized over a weighted average period of less than
1
year.
 
The following table summariz
es information for outstanding options of our employees at
December 
31,
2017:
 
 
 
 
   
Options Outstanding
   
Options Exercisable
 
 
 
 
Range of Exercise
Prices
   
Number
Outstanding as
of December 31,
201
7
   
Weighted
Average
Remaining
Contractual
Life
   
Weighted
Average
Exercise
Price
   
Number
Exercisable
as of
December 31,
201
7
   
Weighted
Average
Exercise
Price
 
                                               
$16.43
 
 
     
63,142
     
3.13
    $
16.43
     
63,142
    $
16.43
 
$17.48
 
 
     
29,849
     
5.14
    $
17.48
     
29,849
    $
17.48
 
$18.43
 
 
     
27,553
     
4.13
    $
18.43
     
27,553
    $
18.43
 
$21.87
 
 
     
25,257
     
6.14
    $
21.87
     
18,947
    $
21.87
 
$16.43
-
$21.87
     
145,801
     
4.25
    $
17.97
     
139,491
    $
17.79
 
 
Restricted S
hare
Awards
/ Deferred S
hare
Awards
 
The following table presents the changes in
restricted share and deferred share awards outstanding and related information for our employees during the years ended
December 31, 2017,
2016
and
2015:
 
   
 
 
Nu
mber of
Awards
   
Weighted
Average Grant
Date Fair Value
Per Share
 
Nonvested shares at
December 31, 2014
   
576,882
    $
19.78
 
Granted
   
1,208,642
     
3.61
 
Vested
   
(248,215
)    
18.17
 
Forfeited
   
(223,745
)    
7.54
 
Nonvested shares at December 31, 201
5
   
1,313,564
    $
7.29
 
Granted
   
584,283
     
1.64
 
Vested
   
(526,628
)    
8.15
 
Forfeited
   
(72,847
)    
7.04
 
Nonvested shares at December 31, 201
6
   
1,298,372
    $
4.41
 
Granted
   
1,655,067
     
3.14
 
Vested
   
(733,147
)    
4.19
 
Forfeited
   
(49,968
)    
3.43
 
Nonvested shares at December 31, 201
7
   
2,170,324
    $
3.54
 
 
The weighted average grant date fair value per share for restricted s
hare and deferred share awards granted during
2017,
2016
and
2015
was
$3.14,
$1.64
and
$3.61,
respectively. The total fair value of restricted share and deferred share awards vested during
2017,
2016
and
2015
was
$2.0
million,
$0.6
million and
$0.9
million, respectively. At
December 31, 2017,
unrecognized compensation cost related to restricted share and deferred share awards was
$4.5
million, which is expected to be recognized over a weighted average period of
1.7
years.
 
Phantom Share Awards
 
Each phantom s
hare award is equal in value to
one
common share. Upon vesting, each recipient will receive a lump sum cash payment equal to the fair market value of a common share on the respective vesting date. These awards are accounted for as a liability that is remeasured at each reporting date until paid.
 
The following table presents the changes in phantom share awards outstanding and related information for our employees during the years ended
December 31,
201
7,
2016
and
2015:
 
   
Nu
mber of Awards
 
Nonvested shares at
December 31, 2014
   
432,881
 
Granted
   
1,920,451
 
Vested
   
(202,284
)
Forfeited
   
(352,848
)
Nonvested shares at December 31, 201
5
   
1,798,200
 
Granted
   
6,831,957
 
Vested
   
(608,230
)
Forfeited
   
(1,751,963
)
Nonvested shares at December 31, 201
6
   
6,269,964
 
Granted
   
750,525
 
Vested
   
(2,207,589
)
Forfeited
   
(263,161
)
Nonvested shares at December 31, 201
7
   
4,549,739
 
 
At
December 31, 2017,
the balance of the liability for the phantom share awards was
$5.3
million.
  For the years ended
December 31, 2017,
2016
and
2015,
we made phantom share cash payments of
$7.1
 million,
$0.5
million and
$0.8
million, respectively.  At
December 31, 2017,
unrecognized compensation cost related to phantom shares was
$7.1
million, as remeasured at
December 31, 2017,
which is expected to be recognized over a weighted average period of
1.3
years. The weighted average grant date fair value of phantom shares granted during the years ended
December 31, 2017,
2016
and
2015
was
$3.27,
$0.91
and
$3.68,
respectively.
 
P
erformance
Share Awards
 
On
February 21, 2017,
we granted
762,497
performance awards under the Civeo Plan, which cliff vest in
three
years on
February 21, 2020.
These awards will be earned in amounts between
0%
and
200%
of the participant’s target performance share award, based on the payout percentage associated with Civeo’s relative total shareholder return (TSR) rank among a peer group of
15
other companies. The awards are being accounted for as equity awards, with a fair value of
$5.20
calculated as of
February 21, 2017.
 
On
February 23, 2016,
we granted
2,400,606
performance awards under the Civeo Plan, which cliff vest in
three
years on
February 23, 2019.
These awards will be earned in amounts between
0%
and
200%
of the participant’s target performance share award, based on the payout percentage associated with Civeo’s relative TSR rank among a peer group of
12
other companies. Shareholder approval to grant these awards as equity awards to be settled in shares was obtained on
May 12, 2016.
Accordingly, the awards are being accounted for as equity awards, with a fair value of
$3.18
calculated as of
May 12, 2016.
 
The fair value of each
performance award was estimated using a Monte Carlo simulation pricing model that uses the assumptions noted in the following table. The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the performance share at the time of grant. The dividend yield on our common shares was assumed to be
zero
since we do
not
currently pay dividends. The expected market price volatility of our common shares was based on an estimate that considers the historical and implied volatility of our common shares as well as a peer group of companies over a time period equal to the expected term of the option. The initial TSR performance was based on historical performance of our common shares and the peer group’s common shares.
 
   
2017
   
2016
 
Risk-free weighted interest rate
   
1.50
%    
0.92
%
Expected volatility
   
90.0
%    
90.0
%
Initial TSR
   
0.04
%    
93.7
%
 
The followi
ng table presents the changes in performance awards outstanding and related information for our employees during the year ended
December 31, 2017
and
2016:
 
   
 
 
Number of
Awards
   
Weighted
Average Grant
Date Fair Value
Per Share
 
Nonvested shares at December 31, 2015
   
--
    $
--
 
Granted
   
2,400,606
     
3.18
 
Vested
   
--
     
--
 
Forfeited
   
(448,922
)    
3.18
 
Nonvested shares at December 31, 2016
   
1,951,684
    $
3.18
 
Granted
   
762,497
     
5.20
 
Vested
   
--
     
--
 
Forfeited
   
(38,699
)    
3.64
 
Nonvested shares at December 31, 2017
   
2,675,482
    $
3.75
 
 
During the year
s ended
December 31 2017
and
2016,
we recognized compensation expense associated with performance awards totaling
$3.0
million and
$1.9
million. At
December 31, 2017,
unrecognized compensation cost related to performance awards was
$5.0
million, which is expected to be recognized over a weighted average period of
1.7
years.